drugset / Trial / NCT04664829
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Phase 1
Completed
12 enrolled
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore · collab
NaSingle-groupOpen-labelTreatment
Summary
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour. The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2025-08-04
- Completion
- 2025-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 200 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |